Expert review

Intracoronary versus intravenous bolus abciximab administration in patients undergoing primary percutaneous coronary intervention with acute ST-elevation myocardial infarction: a pooled analysis of individual patient data from five randomised controlled trials

EuroIntervention 2014;9:1110-1120.

Raffaele Piccolo
Raffaele Piccolo1, MD; Ingo Eitel2, MD; Allan Zeeberg Iversen3, MD; Youlan L. Gu4, MD; Alberto Dominguez-Rodriguez5, MD; Bart J.G.L. de Smet6, MD; Karim D. Mahmoud4, MD; Pedro Abreu-Gonzalez7, MD; Holger Thiele2, MD; Federico Piscione8*, MD
1. Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy; 2. Heart Center, Department of Internal Medicine, Cardiology, University of Leipzig, Leipzig, Germany; 3. Department of Cardiology, Gentofte Univers

Aims: In recent years, intracoronary bolus abciximab has emerged as an alternative to the standard intravenous route in patients with ST-elevation myocardial infarction (STEMI) underg

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

acute myocardial infarctionglycoprotein iib/iiia inhibitorsintracoronary abciximabprimary pci
Read next article
How should I treat a symptomatic post dissection carotid aneurysm?

Latest news